30-day average of 15 articles · scale −100 to +100
Across 15 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Elevance Health news is Bullish (+55)
on a scale from −100 to +100.
That is up 19 points from the previous 30 days (+36).
📈 ELV shares up 33.6% in 12 months despite earnings valuation questions.
⚠️ Elevated behavioral health utilization may limit scaling of cost savings.
Somewhat Bullish +45
Elevance Health (ELV) Stock Looks Reasonable After Raised Earnings Outlook
AI-generated analysis
Key insights
📈 Elevance Health shares have gained 33.6% over the past 12 months, raising questions about whether current earnings fully support the price advance.
📉 The company trades at a P/E ratio of approximately 18.1x, which is well below the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.
💰 Management has lifted its longer-term earnings outlook and flagged potential improvements in Medicaid margins to support future profit growth.
🛡️ Carelon's complex behavioral care programs have shown around 10% cost savings and reduced inpatient admissions, supporting value-based relationships.
🏥 Expansion of home-based CareBridge services into new markets aims to deepen revenue from health services and support margin resilience.
⚠️ Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests cost savings may not scale fast enough across the wider book.
📊 Analyst consensus narratives on Simply Wall St currently split between a bullish view of 9% undervaluation and a bearish view of roughly fair value.
⚖️ Despite a recent lawsuit over alleged fraudulent billing, the market continues to price Elevance Health at a discount to sector norms.
📈 Bullish signals
💰Management has lifted its longer-term earnings outlook, signaling confidence in future profit growth and operational efficiency.
📉The stock trades at a P/E ratio of approximately 18.1x, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x, suggesting potential undervaluation.
🛡️Carelon's behavioral care programs have demonstrated around 10% cost savings and reduced inpatient admissions, indicating strong operational performance.
🏥Expansion of home-based CareBridge services into new markets is expected to deepen value-based relationships and support future margin resilience.
📉 Risk factors
⚠️Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests that projected medical cost savings may not scale fast enough across the wider book.
⚖️A recent lawsuit over alleged fraudulent billing has put a spotlight on the company's risk controls, though the market currently prices the shares at a discount to sector norms.
Article
Elevance Health (ELV) shares have appreciated 33.6% over the past year, prompting investors to assess whether current earnings power justifies the valuation. The company recently raised its longer-term earnings outlook and highlighted potential improvements in Medicaid margins, which could enhance the durability and predictability of future profit growth within an earnings-based valuation framework.
Analysts covering Elevance Health are currently divided on the stock's fair value. Simply Wall St analysis suggests a bullish case where the stock is 9% undervalued, driven by expansion in Carelon's behavioral care programs that have demonstrated approximately 10% cost savings and reduced inpatient admissions. These initiatives aim to deepen value-based relationships and support margin resilience.
Conversely, a bearish perspective views Elevance Health as roughly fairly valued, citing concerns that persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments may prevent the projected medical cost savings from scaling effectively across the wider book of business. Despite these mixed analyst views, the stock trades at approximately 18.1x earnings, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Elevance Health (ELV) shares have appreciated 33.6% over the past year, prompting investors to assess whether current earnings power justifies the valuation. The company recently raised its longer-term earnings outlook and highlighted potential improvements in Medicaid margins, which could enhance the durability and predictability of future profit growth within an earnings-based valuation framework.
Analysts covering Elevance Health are currently divided on the stock's fair value. Simply Wall St analysis suggests a bullish case where the stock is 9% undervalued, driven by expansion in Carelon's behavioral care programs that have demonstrated approximately 10% cost savings and reduced inpatient admissions. These initiatives aim to deepen value-based relationships and support margin resilience.
Conversely, a bearish perspective views Elevance Health as roughly fairly valued, citing concerns that persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments may prevent the projected medical cost savings from scaling effectively across the wider book of business. Despite these mixed analyst views, the stock trades at approximately 18.1x earnings, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.
📈 ELV shares up 33.6% in 12 months despite earnings valuation questions.
📉 ELV trades at 18.1x P/E, well below healthcare sector average of 25.3x.
💰 Management raised outlook citing potential Medicaid margin improvements for growth.
⚠️ Elevated behavioral health utilization may limit scaling of cost savings.
📈 Elevance Health shares have gained 33.6% over the past 12 months, raising questions about whether current earnings fully support the price advance.
📉 The company trades at a P/E ratio of approximately 18.1x, which is well below the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.
💰 Management has lifted its longer-term earnings outlook and flagged potential improvements in Medicaid margins to support future profit growth.
🛡️ Carelon's complex behavioral care programs have shown around 10% cost savings and reduced inpatient admissions, supporting value-based relationships.
🏥 Expansion of home-based CareBridge services into new markets aims to deepen revenue from health services and support margin resilience.
⚠️ Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests cost savings may not scale fast enough across the wider book.
📊 Analyst consensus narratives on Simply Wall St currently split between a bullish view of 9% undervaluation and a bearish view of roughly fair value.
⚖️ Despite a recent lawsuit over alleged fraudulent billing, the market continues to price Elevance Health at a discount to sector norms.
Bullish Signals
Management lifted longer-term earnings outlook.
Stock trades at 18.1x P/E vs sector 25.3x.
Carelon programs show 10% cost savings.
Home-based services expand to new markets.
Risk Factors
Utilization issues may limit projected medical cost savings.
Management has lifted its longer-term earnings outlook, signaling confidence in future profit growth and operational efficiency.
The stock trades at a P/E ratio of approximately 18.1x, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x, suggesting potential undervaluation.
Carelon's behavioral care programs have demonstrated around 10% cost savings and reduced inpatient admissions, indicating strong operational performance.
Expansion of home-based CareBridge services into new markets is expected to deepen value-based relationships and support future margin resilience.
Risk Factors
Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests that projected medical cost savings may not scale fast enough across the wider book.
A recent lawsuit over alleged fraudulent billing has put a spotlight on the company's risk controls, though the market currently prices the shares at a discount to sector norms.
Elevance Health reported stronger-than-expected third-quarter results on October 21, 2026, leading the company to raise its full-year outlook. Operating revenue increased by 0.7 percent year over year to reach $50.4 billion, while adjusted diluted earnings per share climbed to $6.99. These figures reflect a robust performance that sets a higher baseline for future growth projections.
Following the strong quarterly execution, Elevance Health raised its guidance for 2026 adjusted diluted earnings to at least $29.00 per share, up from the previous estimate of $27.00. The company also lifted its GAAP diluted earnings guidance to at least $22.00 per share and increased operating cash flow guidance to at least $6.5 billion for the year.
Looking ahead to 2027, Chief Executive Gail Boudreaux stated that the company expects adjusted diluted earnings-per-share growth of at least 12 percent from a higher 2026 baseline. Management highlighted that membership trends, medical cost control, and the profitability of its Carelon subsidiary remain central to the insurer's investment case for the coming year.
The health insurer noted an improvement in its benefit expense ratio by 70 basis points to 90.6 percent, driven by better performance in Medicare Advantage and Individual ACA segments. However, the company acknowledged lower membership numbers across Medicaid, Medicare Advantage, and employer risk-based businesses, with total medical membership standing at 44.9 million as of September 30, 2026.
📈 Elevance Health raised 2026 EPS guidance to $29.00 after strong Q3 results.
💰 Q3 adjusted EPS reached $6.99 with operating revenue growing 0.7% year over year.
🚀 Management targets at least 12% adjusted earnings growth for 2027 from $26.75 baseline.
🏥 Benefit expense ratio improved 70 bps to 90.6% driven by Medicare Advantage and ACA.
📉 Total medical membership declined 487,000 to 44.9 million across Medicaid and risk-based businesses.
📈 Elevance Health raised its 2026 adjusted diluted earnings guidance to at least $29.00 per share following a strong third quarter.
💰 Operating revenue grew 0.7% year over year to $50.4 billion, while adjusted EPS reached $6.99 in Q3 2026.
🚀 Management targets at least 12% adjusted earnings growth for 2027 from a higher baseline of $26.75 per share.
🏥 The benefit expense ratio improved by 70 basis points to 90.6%, driven by better performance in Medicare Advantage and ACA segments.
📉 Total medical membership declined by 487,000 to 44.9 million as of September 30, 2026, across Medicaid and other risk-based businesses.
💊 Carelon generated $19.3 billion in Q3 operating revenue with a 17% increase in operating gain to $0.9 billion.
📉 Health Benefits revenue rose 3% to $43.4 billion, though operating gain declined due to investments in the long-term operating model.
👩💼 CEO Gail Boudreaux emphasized that membership trends and medical cost control are key tests for the 2027 path.
📊 Operating cash flow guidance was raised to at least $6.5 billion for the full year 2026.
Risk Factors
Medicaid and Medicare Advantage membership fell 487,000 to 44.9 million.
Bullish Signals
Elevance Health raised its 2026 adjusted diluted earnings guidance to at least $29.00 per share, up from a previous estimate of $27.00.
The company lifted its GAAP diluted earnings guidance to at least $22.00 per share and increased operating cash flow guidance to at least $6.5 billion.
Management expects at least 12% adjusted diluted earnings-per-share growth in 2027 from a higher baseline of at least $26.75.
The benefit expense ratio improved by 70 basis points to 90.6%, reflecting better performance in Medicare Advantage and Individual ACA segments.
Carelon generated $19.3 billion of third-quarter operating revenue, a 5% increase from the prior-year quarter.
Carelon's operating gain increased 17% to $0.9 billion, supported by improved specialty-pharmacy profitability and risk-based solutions.
Risk Factors
The company faced lower membership in Medicaid, Medicare Advantage, and employer risk-based businesses during the quarter.
Total medical membership declined by 487,000 to 44.9 million as of September 30, 2026, creating pressure on premium yields.
Health Benefits operating gain declined year over year as Elevance invested in its long-term operating model.
ACR Alpine Capital Research has significantly increased its position in Elevance Health (ELV), adding 25% to its stake in the third quarter to reach 4.9% of its US equity holdings, valued at approximately $357 million. This strategic move positions Elevance as one of the fund's top ten largest positions, reflecting strong institutional confidence in the insurer's recent performance and forward-looking guidance.
Elevance Health has demonstrated consistent upward revision to its earnings outlook throughout 2026, raising its adjusted EPS guidance three times this year to a minimum of $29. The company reported Q3 adjusted EPS of $6.99, driven by operating revenue growth of 0.7% to $50.4 billion, though costs have risen with an operating expense ratio increasing by 90 basis points.
Wall Street analysts maintain a bullish consensus on Elevance, with average price targets currently 15% above the stock's recent trading price. Analysts project earnings growth returning to pre-2026 lows by 2028, reaching approximately $34.57 per share, while the stock trades at a forward multiple of 15x earnings, which is near its five-year historical average.
📈 ACR Alpine Capital Research increased Elevance stake by 25% to $357 million.
📊 Elevance raised 2026 adjusted EPS guidance floor to at least $29.
💰 Q3 operating revenue grew 0.7% to reach $50.4 billion.
Trades at 15x forward earnings, near five-year average.
Analyst targets up 15% above current price.
Q3 operating revenue grew 0.7%.
Risk Factors
Operating expense ratios rose 90 bps in Q3.
2027 EPS growth hinges on hitting 12% target.
Bullish Signals
ACR Alpine Capital Research added 25% to its Elevance Health stake, signaling strong institutional conviction in the company's current valuation and growth trajectory.
Elevance has raised its 2026 earnings guidance three times this year, demonstrating management's confidence in meeting or exceeding adjusted EPS targets.
The stock trades at a forward multiple of 15x earnings, which is close to the company's five-year average and suggests fair valuation relative to historical norms.
Analyst consensus price targets have increased significantly over the past year, with the average target now trading 15% above the current market price.
Elevance reported solid Q3 operating revenue growth of 0.7%, indicating continued business expansion despite macroeconomic headwinds.
Risk Factors
Adjusted operating expense ratios increased by 90 basis points in the third quarter, raising concerns about margin compression and cost control.
Future earnings growth projections are heavily dependent on Elevance successfully hitting its self-imposed 12% adjusted EPS growth target for 2027.
Elevance Health has raised its adjusted earnings outlook for 2026 following a stronger third-quarter operating performance. The company reported third-quarter operating revenue of $50.4 billion, representing a 0.7% increase year-over-year, with adjusted diluted earnings per share reaching $6.99. This improvement was supported by enhanced operating metrics and a net non-operating benefit of $1.85 per share.
Management has updated its forward guidance, raising the 2026 adjusted diluted EPS outlook to at least $29.00 and increasing the operating cash flow forecast to at least $6.5 billion. Additionally, Elevance Health established a higher earnings baseline of at least $26.75 for 2026 and reiterated its expectation for at least 12% adjusted EPS growth in 2027.
Analyst Zacks Research lifted its full-year 2026 EPS forecast to $29.02, though this remains slightly below the broader analyst consensus of $29.18. While the insurer successfully improved its benefit expense ratio to 90.6% in the third quarter, it faced a decline in medical membership of approximately 487,000 members year-over-year as it made targeted investments.
Investors are closely monitoring Medicaid and Medicare Advantage segments, which remain central to the company's investment case. Elevance Health expects its Medicaid margin to bottom out in 2026 before improving in 2027, with a longer-term target range set higher. The market will focus on whether pricing power can effectively catch up with rising care costs and sustain membership growth.
📈 Elevance raised 2026 EPS outlook to $29.00 on strong Q3 results.
💰 Q3 operating revenue hit $50.4 billion, up 0.7% year-over-year.
📉 Medical membership fell 487,000 to 44.9 million despite higher benefits revenue.
🚀 Management expects at least 12% adjusted EPS growth in 2027.
⚖️ Investors watch medical cost trends and pricing catch-up evidence closely.
📈 Elevance Health raised its adjusted 2026 EPS outlook to at least $29.00 following a strong third-quarter operating performance.
💰 Third-quarter operating revenue reached $50.4 billion, up 0.7% from the prior-year period, driven by improved operations.
📉 Medical membership declined by approximately 487,000 year-over-year to roughly 44.9 million despite higher Health Benefits revenue.
💵 Adjusted diluted earnings per share for the third quarter came to $6.99, supported by a net non-operating benefit of $1.85.
🚀 Management reiterated an expectation for at least 12% adjusted EPS growth in 2027 with a higher baseline set.
📊 Zacks Research lifted its 2026 EPS forecast to $29.02, though the estimate remains below the analyst consensus of $29.18.
🏥 The benefit expense ratio improved to 90.6% in the third quarter as the company made targeted investments.
📉 Medicaid margins are expected to reach a trough in 2026 before improving in 2027 with a higher long-term target.
⚖️ Investors will focus on medical cost trends and evidence that pricing is catching up with care costs.
💹 The stock traded at 382.25 euros as of November 7, 2026, facing a test to prove margin improvements can persist.
Risk Factors
Medical membership fell 487k YoY to 44.9M.
Segment operating gain declined in Q3.
Zacks EPS forecast of $29.02 below consensus.
Bullish Signals
Elevance Health raised its adjusted 2026 EPS outlook to at least $29.00 after third-quarter operating performance exceeded expectations.
The company reported third-quarter operating revenue of $50.4 billion, a 0.7% increase year-over-year, demonstrating resilient top-line growth.
Adjusted diluted earnings per share reached $6.99 in the third quarter, supported by improved operating performance and a $1.85 non-operating benefit.
Management set a higher earnings baseline of at least $26.75 for 2026 and reaffirmed its target for at least 12% adjusted EPS growth in 2027.
Zacks Research increased its full-year 2026 EPS forecast to $29.02, signaling analyst confidence in the company's revised guidance.
The benefit expense ratio improved to 90.6% in the third quarter, indicating better cost management despite targeted investments.
Risk Factors
Medical membership fell by approximately 487,000 year-over-year to roughly 44.9 million, raising concerns about member retention or acquisition challenges.
Segment operating gain declined in the third quarter as the company made targeted investments, potentially impacting short-term profitability.
Zacks Research's revised EPS forecast of $29.02 remains below the broader analyst consensus of $29.18, suggesting some analysts remain cautious.
CVS Health (NYSE: CVS) stock tumbled 12% following the announcement of a plan to split into two independent companies by 2028, despite reporting a strong third quarter that beat earnings estimates and raised its full-year outlook. The company intends to separate its pharmacy retail operations from its health insurance and pharmacy benefit management businesses, creating a new CVS Health entity focused on Aetna, Caremark, and specialty care, while the other entity will operate the 9,000-store CVS Pharmacy chain.
The market reaction highlights investor concerns regarding execution risk and potential cost disadvantages associated with dismantling an integrated empire built over two decades. While CEO David Joyner stated the company is acting from a position of strength, analysts worry that separating the pharmacy benefit manager from the retail arm could erode the synergies previously achieved through acquisitions like Aetna and Caremark.
The article notes that competitors such as Elevance Health (NYSE: ELV) and Cigna rose on the news, benefiting from a relative value trade as they avoid CVS's breakup uncertainty. The split is expected to be tax-free for shareholders but leaves both resulting companies exposed to significant one-time separation costs and the challenge of maintaining commercial agreements between the formerly integrated Caremark and CVS Pharmacy units.
📉 CVS stock dropped 12% after announcing a split into two independent companies by 2028.
💰 Q3 revenue hit $108.4B and adjusted EPS reached $2.09, beating estimates before the selloff.
🏗️ CVS plans a tax-free separation of retail pharmacy from health insurance and PBM businesses.
⚠️ Investors worry about execution risk and potential loss of cost advantages from combined operations.
📅 Split completion expected in first half of 2028, exposing company to separation costs until then.
📉 CVS Health stock dropped 12% after announcing a plan to split into two independent publicly traded companies by 2028.
💰 The company reported Q3 2026 revenue of $108.4 billion and adjusted EPS of $2.09, beating consensus estimates before the selloff.
🏗️ CVS plans to separate its retail pharmacy operations from its health insurance and PBM businesses in a tax-free transaction.
👔 CEO David Joyner will lead the new CVS Health entity, while Group President Prem Shah is set to become CEO of CVS Pharmacy.
⚠️ Investors are concerned about execution risk and potential loss of cost advantages from running pharmacy, PBM, and insurance together.
📅 The split is expected to be completed in the first half of 2028, leaving companies exposed to separation costs until then.
🏥 Under the new structure, CVS Health will retain Aetna, Caremark, and Oak Street Health, while CVS Pharmacy will own the retail stores.
📈 Competitors Elevance Health and Cigna rose 4% and 3% respectively as investors rotated away from breakup uncertainty.
🔍 The breakup coincides with bipartisan political scrutiny regarding pharmacy benefit managers owning pharmacies.
Bullish Signals
Stock rose 4% vs CVS breakup fears.
Integrated model favored over unstable rivals.
Bullish Signals
Elevance Health stock rose 4% as investors favored its integrated model over CVS's planned breakup, highlighting a relative value trade within the managed care sector.
The market reaction to CVS suggests that competitors without breakup uncertainty are viewed as more stable investment targets in the current environment.
Risk Factors
Competitor CVS Health is facing significant execution risk and potential margin pressure from separating its pharmacy, PBM, and insurance operations.
The market's negative reaction to CVS implies that investors fear the dismantling of an integrated empire could destroy value previously built through major acquisitions like Aetna.
Elevance Health received a bullish analyst upgrade from Wells Fargo, which raised its price target to USD 492 and maintained an Overweight rating following improved trends in Medicaid, Medicare Advantage, and health exchanges. The bank cited stronger-than-expected third-quarter results as the primary driver for this constructive shift in outlook, noting that Elevance Health has successfully raised its full-year guidance.
Wells Fargo significantly increased its earnings-per-share estimates for Elevance Health, projecting USD 30.28 for 2026, which is 4.5% above consensus. The bank attributes a substantial portion of this growth to core business performance rather than one-time valuation benefits, forecasting continued solid earnings expansion through 2027 and 2028 even without additional Medicaid support.
Elevance Health reported robust third-quarter financials with adjusted diluted earnings per share of USD 6.99 against a consensus of USD 4.70, while revenue reached USD 50.40 billion versus the forecasted USD 49.32 billion. These strong operating metrics provided the necessary backdrop for the analyst to view the company's future growth trajectory more favorably.
The bank utilizes a valuation multiple of 12.5x on estimated 2028 earnings, with scenarios ranging from USD 369 to USD 586 depending on Affordable Care Act and Medicaid margin assumptions. This upgrade highlights the market's growing confidence in Elevance Health's diversified portfolio and its ability to sustain growth across key business lines.
📈 Wells Fargo raised ELV target price to USD 492 with Overweight rating.
💰 Analysts increased 2026 EPS estimate by USD 2.00 to USD 30.28.
📊 ELV beat Q3 expectations with adjusted diluted EPS of USD 6.99.
Elevance Health received a bullish analyst upgrade from Wells Fargo, which raised its price target to USD 492 and maintained an Overweight rating. The bank cited constructive trends in Medicaid, Medicare Advantage, and health insurance exchanges following the company's third-quarter performance.
The report highlights that Elevance Health recently reported stronger-than-expected revenue of USD 50.4 billion and adjusted diluted EPS of USD 6.99, significantly beating consensus estimates. This robust core performance drove a substantial increase in Wells Fargo's full-year 2026 earnings-per-share estimate to USD 30.28.
Analysts at other major firms including Bernstein, BofA Securities, and Guggenheim also increased their price targets following the earnings beat, indicating broad market confidence. The company subsequently raised its full-year outlook, reinforcing positive sentiment around its financial trajectory and operational momentum.
Wells Fargo projects EPS of USD 31.75 for 2027 and USD 39.40 for 2028, noting that solid growth remains possible even without reliance on Medicaid. The valuation analysis suggests a sensitivity to health-plan margins and policy trends, with the current target based on a 12.5x multiple of estimated 2028 earnings.
📈 Wells Fargo raised ELV price target to USD 492 with Overweight rating.
💰 ELV Q3 EPS beat consensus at USD 6.99 vs USD 4.70 estimate.
Elevance Health (ELV) is highlighted as a strong momentum pick, currently holding a Zacks Momentum Style Score of B and a Zacks Rank of #2 (Buy). The article notes that stocks with these specific ratings have historically outperformed the market over subsequent one-month periods, suggesting ELV is poised for continued gains based on its established price trajectory.
The stock has demonstrated significant outperformance relative to both its industry peers and the broader S&P 500. Over the past week, shares rose 2.73% compared to a 1.19% gain in the Zacks Medical Services industry. On a longer timeframe, ELV's monthly price change of 10.57% vastly exceeded the industry average of 0.73%, while quarterly and yearly gains of 7.82% and 31.08% respectively outpaced the S&P 500.
Analyst sentiment remains robust, evidenced by consistent upward revisions to earnings estimates. Over the past two months, five full-year estimates were raised with none lowered, boosting the consensus estimate from $27.19 to $28.12 in 60 days. Additionally, five next-fiscal-year estimates have moved upwards against only one downward revision, reinforcing the bullish outlook for the insurer.
📈 ELV holds Zacks Rank #2 (Buy) with strong outperformance potential.
🚀 Shares rose 31.08% last year, vastly beating S&P 500 returns.
📊 Stock gained 10.57% this month and 7.82% this quarter.
💹 Healthy trading volume of 1.35M shares supports the rising trend.
📝 Analyst estimates rose to $28.12 with five full-year revisions up.
📈 Elevance Health (ELV) holds a Zacks Momentum Style Score of B and a Zacks Rank of #2 (Buy), indicating strong potential for outperformance.
🚀 Shares are up 2.73% in the past week, significantly beating the Zacks Medical Services industry gain of 1.19%.
📊 Over the last month, ELV gained 10.57%, vastly outperforming the industry average of 0.73%.
📈 The stock has increased 7.82% over the past quarter and 31.08% in the last year, exceeding S&P 500 returns.
💹 Trading volume is healthy with a 20-day average of 1,349,678 shares, supporting the rising price trend.
📝 Analyst estimates are trending positive with five full-year revisions raised and none lowered in the last two months.
🔭 The consensus earnings estimate increased from $27.19 to $28.12 over the past 60 days due to upward revisions.
👀 For the next fiscal year, five estimates have moved upwards while only one has been lowered recently.
Bullish Signals
Zacks Rank #2 (Buy) associated with historical outperformance.
Bullish Signals
Elevance Health holds a Zacks Momentum Style Score of B and a Zacks Rank of #2 (Buy), historically associated with outperformance over one-month periods.
Shares are up 2.73% in the past week, significantly outpacing the Zacks Medical Services industry gain of 1.19%.
The stock achieved a monthly price change of 10.57%, vastly exceeding the industry average of 0.73%.
ELV shares have gained 31.08% in the last year, substantially outperforming the S&P 500's 13.12% gain.
The company is trading on a healthy 20-day average volume of 1,349,678 shares, indicating strong buyer interest.
Analyst consensus estimates for the full year have risen from $27.19 to $28.12 over the past 60 days due to five upward revisions and zero downward ones.
Forward-looking guidance is supported by a trend where five next-fiscal-year estimates moved upwards against only one downward revision.
Elevance Health raised its adjusted earnings guidance for 2026 to at least USD 29.00 following the release of its third-quarter results on October 21, 2026. The company reported third-quarter operating revenue of USD 50.4 billion, representing an increase of USD 0.4 billion compared to the same quarter in the previous year.
Financial performance metrics showed improvement with adjusted diluted earnings per share reaching USD 6.99 and GAAP diluted earnings per share at USD 6.27. The benefit expense ratio improved to 90.6 percent from 91.3 percent in the prior year, while operating cash flow for the quarter reached USD 1.3 billion.
The company updated its full-year operating cash flow guidance to at least USD 6.5 billion and declared a fourth-quarter dividend of USD 1.72 per share. Despite a slight decline in medical membership to 44.9 million, the improved expense ratio and strong cash generation support the bullish outlook.
Analyst sentiment remains positive with Guggenheim raising its price target to USD 460 on October 12, 2026. Elevance Health operates through health benefits, pharmacy, and healthcare service businesses with a market capitalization of approximately USD 93.5 billion as of late October 2026.
📈 Elevance raised 2026 adjusted earnings guidance to at least USD 29.00.
Elevance Health reported strong third-quarter financial results for the period ending September 30, 2026, with total revenue reaching USD 51.43 billion, representing a 1.40% increase from the prior year. Shareholders' net income grew to USD 1.37 billion, and diluted earnings per share rose to USD 6.27, driven by improved performance in its Carelon segment.
Analyst firm TD Cowen maintained its Buy rating on Elevance Health stock with a price target of USD 495.00 as of October 23, 2026. The company's market capitalization stands at USD 93.8 billion, and it recently declared a quarterly dividend of USD 1.72 per share payable in December.
Despite a slight decline in total medical membership of 1.10% to 44.88 million, Elevance Health successfully offset this pressure through growth in its Carelon operating revenue, which increased by 5.00% to USD 19.30 billion. The segment also saw an improvement in operating margins to 4.70%, highlighting operational efficiency gains.
The company's Health Benefits segment posted a 1.00% operating margin in the third quarter. Key financial metrics include a trailing price-to-earnings ratio of 18.48 and a 52-week trading range between USD 274.84 and USD 450.69, reflecting investor confidence in its strategic growth initiatives.
📈 Elevance Health Q3 2026 revenue rose 1.40% to USD 51.43 billion.
💰 Net income grew to USD 1.37 billion, boosting EPS to USD 6.27.
🏥 Carelon operating margin improved to 4.70% despite a slight membership drop.
💼 TD Cowen maintains Buy rating with USD 495 price target for ELV.
💸 Quarterly dividend declared at USD 1.72 per share payable December 18, 2026.
📈 Elevance Health reported third-quarter 2026 revenue of USD 51.43 billion, up 1.40% year-over-year.
💰 Shareholders' net income reached USD 1.37 billion, compared to USD 1.19 billion in the same period last year.
📊 Diluted earnings per share increased to USD 6.27 from USD 5.32 a year ago.
🏥 Carelon operating revenue grew by 5.00% to USD 19.30 billion in the third quarter of 2026.
📉 Total medical membership declined slightly by 1.10% to 44.88 million as of September 30, 2026.
🔍 Carelon operating margin improved to 4.70%, up from 4.20% in the prior year period.
💼 TD Cowen maintained a Buy rating with a USD 495.00 price target on October 23, 2026.
📉 The stock trades at a trailing P/E ratio of 18.48 with a market cap of USD 93.8 billion.
💸 Elevance Health declared a quarterly dividend of USD 1.72 per share payable on December 18, 2026.
🏢 The Health Benefits segment posted an operating margin of 1.00% in the third quarter of 2026.
Risk Factors
Medical membership fell 1.10% to 44.88 million by Sept 2026.
Health Benefits margin hit 1.00% vs Carelon's 4.70%.
Bullish Signals
Elevance Health reported a 1.40% year-over-year increase in total revenue to USD 51.43 billion for the third quarter of 2026.
Shareholders' net income grew to USD 1.37 billion, reflecting a significant improvement over the prior year's USD 1.19 billion.
Diluted earnings per share rose to USD 6.27 from USD 5.32, demonstrating strong profitability growth.
Carelon operating revenue expanded by 5.00% to USD 19.30 billion, offsetting membership headwinds.
The Carelon segment improved its operating margin to 4.70%, indicating enhanced operational efficiency.
TD Cowen analyst firm reaffirmed a Buy rating with a USD 495.00 price target, signaling confidence in the stock's upside potential.
Risk Factors
Total medical membership declined by 1.10% to 44.88 million as of September 30, 2026, indicating some pressure on the core health benefits business.
The Health Benefits segment posted a relatively low operating margin of 1.00% in the third quarter compared to Carelon's 4.70%.
Elevance Health reported strong third-quarter financial results and raised its full-year guidance for 2026. The company posted third-quarter operating revenue of USD 50.40 billion, significantly exceeding market expectations. Consequently, the firm increased its diluted earnings-per-share guidance to at least USD 22.00 and adjusted diluted earnings-per-share guidance to at least USD 29.00 for the full year.
In addition to raising earnings forecasts, Elevance Health upgraded its full-year operating cash flow guidance to a minimum of USD 6.50 billion. The company also reported a benefit expense ratio of 90.6 percent for the quarter, indicating effective cost management within its healthcare operations. These positive financial metrics reflect a robust operational performance during the third quarter of 2026.
Beyond financial guidance, Elevance Health announced key leadership changes and shareholder returns. Jeff Park is set to become President of Carelon effective December 1, 2026, signaling strategic growth in its care management division. Furthermore, the company declared a fourth-quarter dividend of USD 1.72 per share, payable on December 18, 2026, reinforcing its commitment to returning value to shareholders.
📈 ELV raised full-year 2026 EPS guidance to at least USD 22.00.
💰 ELV increased adjusted diluted EPS guidance for 2026 to minimum USD 29.00.
📊 ELV third-quarter operating revenue reached USD 50.40 billion.
💵 ELV upgraded full-year 2026 operating cash flow guidance to at least USD 6.50 billion.
🏥 ELV benefit expense ratio stood at 90.6 percent for the quarter.
📈 Elevance Health raised its full-year 2026 diluted earnings-per-share guidance to at least USD 22.00 following strong third-quarter results.
💰 The company increased its adjusted diluted earnings-per-share guidance for 2026 to a minimum of USD 29.00, reflecting improved profitability expectations.
📊 Third-quarter operating revenue reached USD 50.40 billion, demonstrating significant scale and consistent top-line growth for the insurer.
💵 Elevance Health upgraded its full-year 2026 operating cash flow guidance to at least USD 6.50 billion, highlighting strong liquidity generation.
🏥 The benefit expense ratio stood at 90.6 percent for the quarter, indicating efficient management of healthcare claims and costs.
👔 Jeff Park will assume the role of President of Carelon effective December 1, 2026, expanding leadership in the company's care management segment.
💸 Elevance Health declared a fourth-quarter dividend of USD 1.72 per share, payable on December 18, 2026, to shareholders of record as of December 4.
Bullish Signals
Elevance Health raised its full-year 2026 diluted earnings-per-share guidance to at least USD 22.00, signaling strong confidence in future profitability.
The company increased its adjusted diluted earnings-per-share guidance for 2026 to at least USD 29.00, further validating its operational execution.
Third-quarter operating revenue of USD 50.40 billion demonstrates robust top-line growth and market dominance in the health insurance sector.
Elevance Health upgraded its full-year 2026 operating cash flow guidance to at least USD 6.50 billion, providing a strong liquidity buffer for investments or buybacks.
A benefit expense ratio of 90.6 percent in the third quarter reflects disciplined cost control and effective claims management strategies.
The appointment of Jeff Park as President of Carelon strengthens the company's strategic position in high-growth care management services.
Elevance Health (NYSE:ELV) reported third-quarter 2026 results where revenue of $50.4 billion came in slightly above consensus estimates, effectively inline with expectations at a 1.5% gap. However, the company delivered a significant profitability surprise with adjusted EPS of $6.99, representing a roughly 48% beat against the $4.73 consensus. This strong earnings performance drove shares higher in premarket trading as investors focused on the headline surprise despite the revenue result not being a blowout.
The company attributed its financial strength to improved premium yields and growth in CarelonRx product revenue, which helped offset declines in Medicare Advantage, Medicaid, and Employer Group risk membership. Operating efficiency improved with the benefit expense ratio rising 70 basis points to 90.6%, aided by better performance in Medicare Advantage and Individual ACA segments. Management noted that adjusted operating expenses increased slightly due to targeted one-time investments aimed at supporting growth and quality initiatives.
Management raised its 2026 earnings outlook and expressed confidence in delivering at least 12% adjusted EPS growth for 2027 from a higher baseline of at least $26.75. While this 2027 floor sits below the current analyst consensus for FY2026, the raised guidance and strong EPS beat were sufficient to support a 2.2% premarket gain. The stock has extended its recent strength with gains over the last week, two weeks, and month, suggesting the market is rewarding the earnings beat and positive outlook commentary.
⚠️ Note: The provided text contains future dates (2026) and data for Elevance Health (ELV), not the target ticker ELV (Elevance Health). Based on your instruction to focus strictly on the target company, I have extracted the key facts assuming the text refers to Elevance Health.
📈 Q3 2026 revenue hit $50.4B, beating estimates by 1.5%.
💰 Adjusted EPS surged 48% to $6.99, far exceeding consensus.
🛡️ Benefit expense ratio improved 70 bps to 90.6% due to segment performance.
🚀 Management raised 2026 outlook and targets 12% adjusted EPS growth for 2027.
📈 Elevance Health reported Q3 2026 revenue of $50.4 billion, which was approximately 1.5% above consensus estimates and described as inline with expectations.
💰 Adjusted EPS surged to $6.99, a roughly 48% beat against the $4.73 consensus that drove the headline earnings surprise.
📉 Revenue growth was partially offset by lower membership in Medicare Advantage, Medicaid, and Employer Group risk-based plans.
🛡️ The benefit expense ratio improved 70 basis points to 90.6% due to better performance in Medicare Advantage and Individual ACA segments.
🚀 Management raised its 2026 earnings outlook and remains confident in delivering at least 12% adjusted EPS growth for 2027.
📈 Shares rose about 2.2% in premarket trading, extending a strong recent run with gains over the last week, two weeks, and month.
💼 Adjusted operating expenses increased slightly to 11.3% as the company invested in capabilities and growth initiatives.
Risk Factors
Revenue growth offset by lower Medicare Advantage membership counts.
Adjusted operating expense ratio rose to 11.3% for growth.
Health Benefits operating gain declined year over year.
Bullish Signals
Elevance Health delivered a massive adjusted EPS beat of roughly 48%, reporting $6.99 against a consensus of $4.73.
The company raised its 2026 earnings outlook and management remains confident in delivering at least 12% adjusted EPS growth for 2027.
Revenue came in slightly above estimates at $50.4 billion, driven by higher premium yields and increased CarelonRx product revenue.
The benefit expense ratio improved significantly by 70 basis points to 90.6%, reflecting better Medicare Advantage and Individual ACA performance.
Shares gained 2.2% in premarket trading, extending a strong recent trend with double-digit gains over the last two weeks.
Risk Factors
Revenue growth was partly offset by lower membership counts in Medicare Advantage, Medicaid, and Employer Group risk-based plans.
The adjusted operating expense ratio rose to 11.3% as the company made targeted one-time investments to support growth and quality initiatives.
Health Benefits operating gain declined year over year, indicating some pressure in that specific segment.
Elevance Health, Inc. (NYSE: ELV) is a major healthcare plan provider with a market capitalization of $92.88 billion and a stock price of $428.26, trading near its 52-week high. The company demonstrates strong financial stability with an earnings per share of $22.59, a return on equity of 11.13%, and significant free cash flow exceeding $4.3 billion. These metrics highlight efficient capital management and the ability to fund operations while rewarding shareholders through dividends.
The firm reported revenue growth of 1.40% and maintains a forward P/E ratio of 14.47, suggesting a moderate valuation relative to peers with an average analyst target price of $451.71 indicating potential upside. Analyst sentiment is predominantly positive, reflected in 14 Buy ratings versus 8 Hold ratings, with no Sell recommendations. The consensus target price range spans from $393.00 to $492.00, affirming confidence in the company's strategic direction and execution capabilities.
Technically, Elevance Health is positioned above its 50-day and 200-day moving averages, signaling sustained upward momentum despite an RSI indicating oversold conditions which could present a buying opportunity. The company, formerly Anthem Inc., operates through four key segments offering health plans to individuals, employers, and government programs like Medicare and Medicaid. Its diverse portfolio includes specialty insurance, pharmacy services via CarelonRx, and advanced healthcare solutions under brands such as Anthem Blue Cross and Blue Shield.
📈 ELV trades near 52-week high with $451.71 analyst target implying 5.48% upside.
💰 Reported EPS of $22.59 and free cash flow exceeding $4.3 billion support dividends.
📊 Revenue grew 1.40% via health benefits, CarelonRx pharmacy services, and broader healthcare solutions.
👍 Analyst sentiment is positive with 14 Buy ratings against zero Sell ratings.
🏢 Formerly Anthem Inc., ELV serves individual, employer, and government clients across four segments.
📈 Elevance Health trades at $428.26 near its 52-week high with a forward P/E of 14.47 and an average analyst target price of $451.71 suggesting 5.48% upside.
💰 The company reported EPS of $22.59, a return on equity of 11.13%, and free cash flow exceeding $4.3 billion to support operations and dividends.
📊 Revenue growth of 1.40% reflects steady expansion across health benefits, pharmacy services through CarelonRx, and broader healthcare-related services.
👍 Analyst sentiment is positive with 14 Buy ratings and 8 Hold ratings against no Sell ratings, affirming confidence in strategic execution.
📉 Technical indicators show the stock above 50-day ($403.84) and 200-day ($369.22) moving averages with an RSI of 17.11 suggesting oversold territory.
🏢 Elevance Health, formerly Anthem Inc., operates through four key segments serving individual, employer, and government clients including Medicare and Medicaid.
💵 The company offers a dividend yield of 1.61% with a payout ratio of 30.37%, balancing shareholder rewards with retained earnings for growth.
🛡️ Strategic positioning includes specialty insurance products and advanced healthcare solutions leveraging the Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon brands.
Bullish Signals
Elevance Health trades near its 52-week high of $428.43 with a forward P/E of 14.47, indicating strong investor confidence and moderate valuation relative to peers.
The company boasts significant free cash flow of over $4.3 billion, providing substantial flexibility to fund operations, pay dividends, and reinvest in growth opportunities.
Analyst sentiment is predominantly positive with 14 Buy ratings and no Sell ratings, affirming confidence in the company's strategic direction and execution capabilities.
The stock is positioned above both its 50-day and 200-day moving averages, indicating sustained upward momentum and technical strength.
Elevance Health offers a dividend yield of 1.61% with a payout ratio of 30.37%, ensuring a balanced approach between rewarding shareholders and retaining earnings.
Elevance Health, Inc. (NYSE:ELV) is identified as the 18th pick on a list of Goldman Sachs' top fund manager stock picks, specifically among stocks where large-cap, growth, and value mutual fund managers hold overweight positions relative to benchmarks. The article highlights that ELV was included in this ranking based on data from Q2 2024, positioning it as a notable holding for institutional investors despite the broader market focus on artificial intelligence.
The company is described as a diversified American healthcare services provider with a significant commercial market share of 12% and a large customer base of 47.5 million members. Fund manager Artisan Partners noted in its Q2 2024 investor letter that Elevance shares rose 5% during the quarter, driven by strong profit growth in its Carelon Services business and successful navigation of Medicaid redetermination challenges.
Analysts view ELV as an attractive investment proposition trading at 13X earnings with expectations for long-term earnings growth exceeding 12%. However, the article notes that the stock remains vulnerable to government regulations affecting fee structures and membership numbers, citing an 8% decline in shares during 2023 due to drops in Medicaid memberships. The company is also actively working with a private equity firm to expand its presence in the primary care market.
📈 ELV ranks 18th on Goldman Sachs' top fund manager stock picks for Q2 2024.
📊 Company holds 12% commercial health insurance market share with 47.5 million members.
📈 Shares rose 5% in Q2 2024 driven by Carelon Services profit growth.
💰 ELV trades at 13X earnings with projected long-term earnings growth over 12%.
⚠️ Stock declined 8% in 2023 due to reduced Medicaid memberships after pandemic bumps.
📈 Elevance Health ranks 18th on Goldman Sachs' list of top fund manager stock picks based on Q2 2024 overweight positions.
📊 The company holds a 12% market share in the commercial health insurance sector with 47.5 million members.
📈 Shares rose 5% in Q2 2024 according to Artisan Partners, driven by profit growth in Carelon Services.
💰 ELV trades at 13X earnings with analysts projecting long-term earnings growth of over 12%.
⚠️ The stock faced an 8% decline in 2023 due to reduced Medicaid memberships following pandemic bumps.
🤝 Elevance is partnering with a private equity firm to grow its share in the primary care market.
Bullish Signals
Ranks 18th on Goldman Sachs' top fund manager stock picks.
Shares rose 5% in Q2 2024 due to Carelon Services profit growth.
Trades at attractive 13X earnings multiple with >12% long-term growth.
Bullish Signals
Elevance Health ranks 18th on Goldman Sachs' list of top fund manager stock picks, indicating strong institutional interest.
Shares rose 5% during Q2 2024 as reported by Artisan Partners due to strong profit growth in the Carelon Services business.
The company is trading at an attractive 13X earnings multiple with expectations for long-term earnings growth exceeding 12%.
Risk Factors
Elevance Health's shares closed 8% lower in 2023 due to a drop in Medicaid memberships following the pandemic.
The company remains vulnerable to government regulations that can limit fees charged by insurance providers.
Wall Street analysts project Elevance Health (ELV) to report Q3 earnings of $4.66 per share, representing a 22.7% decline year-over-year. Revenue estimates stand at $48.6 billion, down 3% from the prior-year period, with no recent revisions to the consensus EPS forecast over the last 30 days.
Analyst expectations for specific revenue segments show mixed performance, with 'Revenues- Premiums' estimated to drop by 4.9% to $39.73 billion and 'Net investment income' falling 23.8% to $476.23 million. Conversely, 'Product revenue' is forecast to grow by 5.3% to $6.49 billion, while 'Service fees' are expected to rise 5.7% to $2.26 billion.
Membership metrics indicate a contraction in total medical membership to an estimated 44.26 million, down from 45.37 million the previous year. Specific segments like Medicare Advantage and Commercial Risk-Based Individual memberships are projected to decline, whereas Commercial Fee-Based membership is expected to increase slightly to 27.46 million.
The consensus Benefit Expense Ratio is predicted to remain stable at 91.4%, matching the prior-year quarter's reported figure of 91.3%. Despite these fundamental declines in earnings and premiums, ELV shares have gained 3.4% over the past month, outperforming the S&P 500, and maintain a Zacks Rank #2 (Buy) rating.
Barclays raised its price target for Elevance Health from USD 457 to USD 469 on October 7, 2026, maintaining an Overweight rating. This bullish action occurred ahead of the company's scheduled third-quarter earnings report on October 21, 2026, which analysts are closely watching following a strong second quarter.
Elevance Health reported robust second-quarter 2026 financials with revenue reaching USD 49.83 billion and adjusted earnings per share of USD 7.45. This performance significantly beat the consensus estimate of USD 6.21 for EPS, demonstrating strong execution against market expectations.
The company is expanding its Medicare Advantage portfolio for coverage starting January 1, 2027, including new Dual Eligible and Chronic Condition Special Needs Plans. However, recent challenges persist as Cantor Fitzgerald maintained a lower USD 450 target following Elevance's drop in 2027 Medicare Stars rating to 47 percent from 54 percent in the prior year.
📈 Barclays raised ELV price target to USD 469 with Overweight rating.
📊 Adjusted earnings per share for the second quarter were USD 7.45, beating the consensus estimate of USD 6.21 by USD 1.24.
🚀 Elevance Health announced new Medicare Advantage offerings including Dual Eligible and Chronic Condition Special Needs Plans effective January 1, 2027.
⚠️ The company's 2027 Medicare Stars rating fell to 47 percent from 54 percent in 2026, prompting Cantor Fitzgerald to maintain a lower USD 450 price target.
📅 Third-quarter 2026 results are scheduled for release on October 21, 2026, at 6:00 a.m. EDT.
Bullish Signals
Barclays raised price target to USD 469 with Overweight rating.
Risk Factors
Cantor lowered $450 target after Medicare Stars rating drop.
Bullish Signals
Barclays raised its price target for Elevance Health from USD 457 to USD 469 on October 7, 2026, maintaining an Overweight rating.
Elevance Health stock rose 2.79 percent to EUR 371.95 on October 9, 2026, trading at a P/E ratio of 18.5 and a market capitalization of USD 90.3 billion. The NYSE quote stood at USD 416.21, positioning the stock 4.59 percent below its 52-week high of USD 436.24 while remaining significantly above its low.
Analyst sentiment remains positive with an average 12-month target price of USD 440.90 from 23 analysts. Barclays recently raised its target to USD 469.00, maintaining an Overweight rating, while MarketBeat data indicates that 15 of the 23 analysts recommend buying the stock.
The company is preparing to release its third-quarter 2026 financial results on October 21, 2026, ahead of a conference call scheduled for 8:30 a.m. EDT. Trading volume increased by 5.24 percent compared to the average, reflecting active investor interest in the healthcare insurer's performance.
⚠️ Note: The provided text contains factual errors regarding the target ticker (ELV) and currency (EUR/USD mix). As per instructions to keep key facts, these points are condensed but retain the original data for accuracy to the source text.
📈 ELV stock gained 2.79% to EUR 371.95 on October 9, 2026.
💰 ELV trades at P/E 18.5 with USD 90.3 billion market cap.
🎯 Analysts target USD 440.90, implying upside potential for ELV.
📊 Barclays raised ELV price target to USD 469.00 with Overweight rating.
📈 Elevance Health stock gained 2.79 percent to EUR 371.95 on October 9, 2026.
💰 The company trades at a P/E ratio of 18.5 with a market capitalization of USD 90.3 billion.
🎯 Analysts maintain an average 12-month target price of USD 440.90, suggesting upside potential.
📊 Barclays raised its price target to USD 469.00 while keeping an Overweight rating on the stock.
🗓️ Third-quarter 2026 financial results are scheduled for release on October 21, 2026.
📉 The NYSE quote is currently 4.59 percent below its 52-week high of USD 436.24.
Risk Factors
Stock trades 4.59% below 52-week high of USD 436.24.
Volume rose to 1,248,089 shares without confirming breakout.
Bullish Signals
Elevance Health stock rose 2.79 percent to EUR 371.95, indicating positive market sentiment.
Barclays raised its price target from USD 457.00 to USD 469.00 while maintaining an Overweight rating.
MarketBeat data shows that 15 out of 23 analysts recommend buying the stock, reflecting strong buy-side interest.
Risk Factors
The stock is trading 4.59 percent below its 52-week high of USD 436.24, indicating some near-term consolidation.
Trading volume increased to 1,248,089 shares, which is above the average but does not confirm a breakout.
Elevance Health received a reaffirmed Buy rating from Bernstein on October 5, 2026, with the analyst maintaining a price target of USD 488.00. At the time of the report, Elevance Health stock was trading around EUR 352.45 (USD 394.51), sitting below its 52-week high of USD 436.24 but above the primary market quote. The large-cap insurer has a market capitalization of approximately USD 85.6 billion, reflecting its significant position in the healthcare plans sector.
Financial performance for the second quarter of 2026 showed mixed results, with revenue growing by 1.39% to USD 50.47 billion compared to the prior year. However, net profit declined significantly by 16.09%, dropping from USD 1.74 billion to USD 1.46 billion. This divergence between top-line growth and bottom-line contraction highlights increasing pressure on operating costs and medical spending, which will be central to future earnings discussions.
Looking ahead, Elevance Health raised its full-year 2026 adjusted earnings-per-share guidance to at least USD 27.00. The company is scheduled to release its third-quarter 2026 results on October 21, 2026, providing investors a key checkpoint to evaluate the sustainability of revenue growth against rising medical cost trends and the recent profit decline reported in Q2.
Analysts will be closely monitoring how management addresses the margin compression evident in the second quarter during the upcoming earnings call. The gap between the current trading price and Bernstein's target suggests potential upside if the company can successfully navigate the challenging cost environment while maintaining its revenue trajectory.
📈 Bernstein reaffirmed a Buy rating for Elevance Health on October 5, 2026, keeping the price target at USD 488.00.
💰 Q2 2026 revenue increased by 1.39% to USD 50.47 billion, demonstrating continued top-line growth in the healthcare sector.
📉 Net profit fell sharply by 16.09% to USD 1.46 billion in Q2 2026, signaling rising operational or medical cost pressures.
🎯 Management raised full-year 2026 adjusted earnings-per-share guidance to at least USD 27.00 despite recent quarterly headwinds.
📅 The company will report third-quarter 2026 results on October 21, 2026, with management commentary scheduled for 8:30 a.m. EDT.
📈 Bernstein reaffirmed a Buy rating for Elevance Health on October 5, 2026, keeping the price target at USD 488.00.
💰 Q2 2026 revenue increased by 1.39% to USD 50.47 billion, demonstrating continued top-line growth in the healthcare sector.
📉 Net profit fell sharply by 16.09% to USD 1.46 billion in Q2 2026, signaling rising operational or medical cost pressures.
🎯 Management raised full-year 2026 adjusted earnings-per-share guidance to at least USD 27.00 despite recent quarterly headwinds.
📅 The company will report third-quarter 2026 results on October 21, 2026, with management commentary scheduled for 8:30 a.m. EDT.
📊 Elevance Health trades at a market capitalization of USD 85.6 billion, maintaining its status as a large-cap healthcare leader.
📉 The stock is currently trading below its 52-week high of USD 436.24 but remains above the primary market quote of USD 394.51.
Risk Factors
Net profit fell 16.09% to $1.46B in Q2 2026.
Rising medical costs threaten future profitability despite revenue growth.
Bullish Signals
Bernstein maintained a Buy rating and a USD 488.00 price target for Elevance Health, indicating analyst confidence in the stock's long-term prospects.
The company raised its full-year 2026 adjusted earnings-per-share guidance to at least USD 27.00, demonstrating management's ability to set ambitious yet achievable financial goals.
Revenue grew by 1.39% year-over-year in Q2 2026 to reach USD 50.47 billion, showing resilience and continued market expansion despite macroeconomic headwinds.
Risk Factors
Net profit declined by 16.09% to USD 1.46 billion in Q2 2026, raising concerns about margin compression and rising medical spending costs.
The significant drop in net income despite revenue growth suggests that operating expenses or claims costs are outpacing top-line gains, a key risk for future profitability.
Elevance Health is preparing to report third-quarter earnings on October 21, 2026, with analysts forecasting adjusted earnings per share of USD 4.72. This figure represents a significant year-over-year decline compared to the USD 6.03 reported in the same quarter last year, driven primarily by elevated costs within its Medicaid portfolio.
Despite the anticipated weakness in quarterly comparisons, management has raised its full-year 2026 adjusted diluted earnings per share guidance to at least USD 27 and increased operating cash flow guidance to at least USD 6 billion. The company maintains confidence in returning to at least 12% adjusted earnings per share growth in 2027.
The second quarter showed mixed results with operating revenue growing modestly by 0.8% year over year to USD 49.80 billion, while medical membership ended at 44.9 million. The upcoming report will test whether strong second-half execution can offset the pressure from lower quarterly comparisons and persistent Medicaid margin challenges.
⚠️ Elevance Health Q3 EPS forecast drops 21.7% to USD 4.72.
💰 Company raises full-year 2026 EPS guidance to at least USD 27.
📈 Management projects at least 12% adjusted EPS growth for fiscal 2027.
🏥 Medicaid operations face negative 1.75% full-year operating margin outlook.
📅 October 21 earnings report critical for offsetting comparison pressure.
📉 Elevance Health faces a challenging third-quarter comparison with adjusted earnings per share forecast at USD 4.72, down 21.70% from the prior year.
💰 The company raised its full-year 2026 adjusted diluted earnings per share guidance to at least USD 27 and lifted operating cash flow guidance to at least USD 6 billion.
📊 Second-quarter operating revenue increased by 0.8% year over year to reach USD 49.80 billion, exceeding management's previous outlook.
🏥 Medicaid operations are under pressure with elevated utilization and a full-year operating margin outlook of negative 1.75%.
📈 Management remains confident in achieving at least 12% adjusted earnings per share growth for fiscal year 2027.
📅 The company has a market capitalization of USD 84.3 billion as of September 30, 2026, with its stock trading below the yearly high.
🎯 The upcoming October 21 earnings report will be critical for determining if second-half execution can offset year-over-year comparison pressure.
Risk Factors
Q3 EPS forecast drops 21.70% to USD 4.72 vs last year's USD 6.03.
Medicaid unit margin outlook is negative 1.75%, pressuring overall profitability.
Bullish Signals
Elevance Health raised its full-year 2026 adjusted diluted earnings per share guidance to at least USD 27, signaling strong management confidence in future profitability.
The company lifted its operating cash flow guidance to at least USD 6 billion for the fiscal year, indicating robust liquidity generation.
Second-quarter operating revenue grew by 0.8% year over year to USD 49.80 billion, demonstrating resilience in a mixed market environment.
Management reaffirmed confidence in returning to at least 12% adjusted earnings per share growth in fiscal 2027.
Risk Factors
Analysts forecast third-quarter adjusted earnings per share of USD 4.72, which is a significant 21.70% decline compared to the USD 6.03 reported last year.
The Medicaid business unit faces elevated utilization and a full-year operating margin outlook of negative 1.75%, creating pressure on overall profitability.
Elevance Health raised its full-year 2026 adjusted earnings per share (EPS) guidance to at least $27.00 following a strong second quarter performance. The company reported Q2 EPS of $7.45, significantly beating analyst consensus estimates of $6.21. This positive momentum was driven by improved operating revenue of $49.8 billion and robust cash flow generation of $1.9 billion in the quarter.
The stock price stood at $396.09 on September 25, 2026, trading below its 52-week high but reflecting investor interest in the company's strategic outlook. While Medicare Advantage performance has improved following recent portfolio actions, the company faces ongoing pressure from Medicaid costs due to elevated utilization rates, which impacted the operating margin outlook for that segment.
Looking ahead, Elevance Health projects at least 12% adjusted EPS growth for 2027, contingent on successful execution across its diverse business lines. The central challenge for investors remains whether the gains in Medicare Advantage and expansion of Carelon can sufficiently offset persistent cost pressures within the Medicaid portfolio to sustain long-term profitability.
⚠️ Medicaid segment faces negative 1.75% Q2 operating margin outlook due to high utilization.
💰 Q2 EPS of $7.45 beat estimates by $1.24, raising full-year guidance to $27.00.
📈 Stock traded at $396.09 on Sept 25, 2026, down 9.20% from its 52-week high.
🚀 Company projects at least 12% adjusted EPS growth for fiscal year 2027.
🔍 Investors assess if Carelon expansion can offset persistent Medicaid cost pressures.
📈 Elevance Health raised its full-year 2026 adjusted EPS guidance to at least $27.00 per share following a strong Q2 performance.
💰 The company reported Q2 EPS of $7.45, beating analyst consensus estimates of $6.21 by $1.24.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)